Pradžia › Kraujos vėžys › Pennsylvania
Kraujos vėžys klinikiniai tyrimai Pennsylvania
21 tyrimai dėl Kraujos vėžys ieško dalyvių vietose Pennsylvania.
Miestai Pennsylvania
Oficialus tyrimo tekstas (anglų kalba)
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- University of Pennsylvania ( Site 0010), Philadelphia
- Fox Chase Cancer Center ( Site 0042), Philadelphia
- UPMC Hillman Cancer Center ( Site 0008), Pittsburgh
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT03486873Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Geisinger Medical Center, Danville
- ir dar 7
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 40 iki 75 · Visoms lytims · Atnaujinta 2026-10-02 · NCT05334069Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Philadelphia, Philadelphia
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 0 iki 38 · Visoms lytims · Atnaujinta 2026-10-01 · NCT06131801Genomic Profiling in Cancer Patients
- Lehigh Valley Health Network, Allentown
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-09-24 · NCT01775072Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- UPMC Hillman Cancer Center, Pittsburgh
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT03816345Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Penn State Hershey Medical Center, Hershey
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-21 · NCT07648264Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Christiana Care Health System-Concord Health Center, Chadds Ford
- ir dar 18
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-09-17 · NCT04242095A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- Cancer Care Associates of York, York
Renkami dalyviaiStebimasis tyrimas
Amžius 0 ir vyresni · Visoms lytims · Atnaujinta 2026-09-02 · NCT07154823Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Pennsylvania, Philadelphia
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-20 · NCT07007312A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Penn State Milton S. Hershey Cancer Center, Hershey
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh, Pittsburgh
- ir dar 3
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-07-06 · NCT01351545Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Penn Medicine - Abramson Cancer Center Perelman, Philadelphia
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-24 · NCT04068597Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
- Children's Hospital of Philadelphia, Philadelphia
Renkami dalyviaiStebimasis tyrimas
Iki 30 metų · Visoms lytims · Atnaujinta 2026-06-18 · NCT06579469Allergy Delabeling in Antibiotic Stewardship - Intervention
- Hospital of the University of Pennsylvania, Philadelphia
Renkami dalyviai4 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-17 · NCT07133074Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
- Hospital of the University of Pennsylvania, Philadelphia
Renkami dalyviai1/2 fazėLaukiami sveiki savanoriai
Amžius nuo 12 iki 85 · Visoms lytims · Atnaujinta 2026-06-11 · NCT04959175A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
- Children's Hospital of Philadelphia, Philadelphia
Renkami dalyviai3 fazė
Amžius nuo 2 iki 18 · Visoms lytims · Atnaujinta 2026-05-05 · NCT05711667CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- UPMC Hilman Cancer Center, Pittsburgh
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-16 · NCT03328078Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
- Penn State Cancer Institute, Hershey
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-03 · NCT06926595A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Hospital of the University of Pennsylvania, Philadelphia
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-13 · NCT05735184Home Blood Transfusions
- Thomas Jefferson University Hospital, Philadelphia
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-12-16 · NCT07121140Lifestyle Intervention for Veterans With Blood Cancer: Tele-Intervention
- VA Pittsburgh Healthcare System, Pittsburgh
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-07-10 · NCT07058571Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital of Philadelphia, Philadelphia
Renkami dalyviai1 fazė
Amžius nuo 1 iki 21 · Visoms lytims · Atnaujinta 2024-12-06 · NCT05476770Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.